Login / Signup

Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice.

Yuanbojiao ZuoChen ZhangYuan ZhouHaiwen LiWeidong XiaoRoland W HerzogJie XuJifeng ZhangY Eugene ChenRenzhi Han
Published in: Cell & bioscience (2023)
These results highlight the promise of liver-targeted Angptl3 base editing for blood lipid control.
Keyphrases
  • crispr cas
  • fatty acid
  • cancer therapy
  • big data
  • type diabetes
  • drug delivery
  • gene therapy
  • artificial intelligence
  • machine learning
  • insulin resistance